Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064)

AIDS Patient Care and STDs

Volumn 28, Issue 4, 2014, Pages 206-217

  Haley, Danielle F ^a,b   Lucas, Jonathan ^a   Golin, Carol E ^c   Wang, Jing ^d   Hughes, James P ^d,e   Emel, Lynda ^d   El Sadr, Wafaa ^f   Frew, Paula M ^b,g   Justman, Jessica ^f   Adimora, Adaora A ^c   Watson, Christopher Chauncey ^h   Mannheimer, Sharon ^f,i   Rompalo, Anne ^j   Soto Torres, Lydia ^k   Tims Cook, Zandraetta ^l   Carter, Yvonne ^c   Hodder, Sally L ^m  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Department of Medicine   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

ⁱ HARLEM HOSPITAL CENTER   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l EMORY CENTER FOR AIDS RESEARCH   (United States)

^m RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH CARE FINANCING; HEALTH CARE NEED; HIGH RISK POPULATION; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN RELATION; LOWEST INCOME GROUP; POVERTY; RACE; RESPONSIBILITY; RISK FACTOR; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV SEROPREVALENCE; HUMANS; INTERPERSONAL RELATIONS; MIDDLE AGED; MOTIVATION; MULTIVARIATE ANALYSIS; OFFICE VISITS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT DROPOUTS; PATIENT PARTICIPATION; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84898743985     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0366     Document Type: Article

References (49)

1. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-Forgotten but not gone. N Engl J Med 2010;362:967-970.
2. McDavid K, Li J, Lee LM. Racial and ethnic disparities in HIV diagnoses for women in the United States. J Acquir Immune Defic Syndr 2006;42:101-107.
3. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011. 2013;23.
4. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010. HIV Surveillance Supplemental Report, 2012. December 2012.
5. Aziz M, Smith KY. Challenges and successes in linking HIV-infected women to care in the United States. Clin Infect Dis 2011;52:S231-S237.
6. National Institutes of Health: Office of Extramural Research. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research-Amended, October, 2001. http://grants.nih.gov/grants/funding/ women-min/guidelines-Amended-10-2001.htm. Accessed February 8, 2013.
7. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin, 2001.
8. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: Impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol 2001;154:563-573.
9. BeLue R, Taylor-Richardson KD, Lin J, Rivera AT, Grandison D. African Americans and participation in clinical trials: Differences in beliefs and attitudes by gender. Contemp Clin Trials 2006;27:498-505.
10. Smith YR, Johnson AM, Newman LA, Greene A, Johnson TR, Rogers JL. Perceptions of clinical research participation among African American women. J Womens Health (Larchmt) 2007;16:423-428.
11. Humphreys K, Weingardt KR, Harris AH. Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research. Alcohol Clin Exp Res 2007;31:988-995.
12. Chandra A, Paul DP. African American participation in clinical trials: Recruitment difficulties and potential remedies. Hosp Top 2003;81:33-38.
13. Shaya FT, Gbarayor CM, Huiwen Keri Yang, Agyeman-Duah M, Saunders E. A perspective on African American participation in clinical trials. Contemp Clin Trials 2007;28: 213-217.
14. Squires K, Feinberg J, Bridge DA, et al. Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS 2013;27:352-362.
15. Squires KE, Johnson M, Yang R, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 2011;66:363-370.
16. Falcon R, Bridge DA, Currier J, et al. Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt). 2011;20:1043-1050.
17. Hodder SL, Justman J, Hughes JP, et al. HIV acquisition among women from selected areas of the United States: A cohort study. Ann Intern Med 2013;158:10-18.
18. Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health 2011;101:128-136.
19. Aidala A, Cross JE, Stall R, Harre D, Sumartojo E. Housing status and HIV risk behaviors: Implications for prevention and policy. AIDS Behav 2005;9:251-265.
20. Hessol NA, Weber KM, Holman S, et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health (Larchmt) 2009;18:1627-1637.
21. Seage GR, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001;153:619-627.
22. Brown-Peterside P, Chiasson MA, Ren L, Koblin BA. Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine preparedness study in New York City. J Urban Health 2000;77:425-437.
23. Brown-Peterside P, Rivera E, Lucy D, et al. Retaining hardto-reach women in HIV prevention and vaccine trials: Project ACHIEVE. Am J Public Health 2001;91:1377-1379.
24. Koblin BA, Metch B, Novak RM, et al. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: Longitudinal results of HVTN 906. J Acquir Immune Defic Syndr 2013; 63:239-244.
25. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9:117-125.
26. Toth M, Messer LC, Quinlivan EB. Barriers to HIV care for women of color living in the Southeastern U.S. are associated with physical symptoms, social environment, and self-determination. AIDS Patient Care STDS. 2013; 27: 613-620.
27. Messer LC, Quinlivan EB, Parnell H, et al. Barriers and facilitators to testing, treatment entry, and engagement in care by HIV-positive women of color. AIDS Patient Care STDS 2013;27:398-407.
28. Bofill L, Waldrop-Valverde D, Metsch L, Pereyra M, Kolber MA. Demographic and psychosocial factors associated with appointment attendance among HIV-positive outpatients. AIDS Care 2011;23:1219-1225.
29. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
30. Stein JA, Andersen RM, Robertson M, Gelberg L. Impact of hepatitis B and C infection on health services utilization in homeless adults: A test of the Gelberg-Andersen Behavioral Model for Vulnerable Populations. Health Psychol 2012;31:20-30.
31. Stein JA, Andersen R, Gelberg L. Applying the Gelberg-Andersen behavioral model for vulnerable populations to health services utilization in homeless women. J Health Psychol. 2007;12(5):791-804.
32. Haley DF, Golin C, El-Sadr W, et al. Venue-based recruitment of women at elevated risk for HIV: An HIV prevention trials network study. J Women's Health (in press).
33. Cottler LB, Compton WM, Ben-Abdallah A, Horne M, Claverie D. Achieving a 96.6 percent follow-up rate in a longitudinal study of drug abusers. Drug Alcohol Depend 1996;41:209-217.
34. Hunt JR, White E. Retaining and tracking cohort study members. Epidemiol Rev 1998;20:57-70.
35. Scott CK. A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers. Drug Alcohol Depend 2004;74:21-36.
36. Group NCHSPT. Design and integration of ethnography within an international behavior change HIV/sexually transmitted disease prevention trial. AIDS 2007;21 Suppl 2:S37-S48.
37. Prins A, Ouimette P, Kimerling RP, et al. The primary care PTSD screen (PC-PTSD): Development and operating characteristics. Primary Care Psychiat 2004:5.
38. DiClemente RJ, Wingood GM, Crosby RA, et al. A prospective study of psychological distress and sexual risk behavior among black adolescent females. Pediatrics 2001; 108:E85.
39. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
40. Metch B, Frank I, Novak R, et al. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav 2013; 17:760-772.
41. Corbie-Smith G, Moody-Ayers S, Thrasher AD. Closing the circle between minority inclusion in research and health disparities. Arch Intern Med 2004;164:1362-1364.
42. Gilliss CL, Lee KA, Gutierrez Y, et al. Recruitment and retention of healthy minority women into community-based longitudinal research. J Womens Health Gend Based Med 2001;10:77-85.
43. Morin SF, Maiorana A, Koester KA, Sheon NM, Richards TA. Community consultation in HIV prevention research: A study of community advisory boards at 6 research sites. J Acquir Immune Defic Syndr 2003;33:513-520.
44. Leonard NR, Lester P, Rotheram-Borus MJ, Mattes K, Gwadz M, Ferns B. Successful recruitment and retention of participants in longitudinal behavioral research. AIDS Educ Prev 2003;15:269-281.
45. Frew PM, Hou SI, Davis M, et al. The likelihood of participation in clinical trials can be measured: The Clinical Research Involvement Scales. J Clin Epidemiol 2010; 63:1110-1117.
46. Boerma JT, Weir SS. Integrating demographic and epidemiological approaches to research on HIV/AIDS: The proximatedeterminants framework. J Infect Dis 2005;191:61-67.
47. McNeil R, Guirguis-Younger M, Dilley LB, Aubry TD, Turnbull J, Hwang SW. Harm reduction services as a pointof-entry to and source of end-of-life care and support for homeless and marginally housed persons who use alcohol and/or illicit drugs: A qualitative analysis. BMC Public Health 2012;12:312.
48. Breitkopf CR, Loza M, Vincent K,Moench T, Stanberry LR, Rosenthal SL. Perceptions of reimbursement for clinical trial participation. J Empir Res Hum Res Ethics 2011;6:31-38.
49. Boehme AK, Davies SL, Moneyham L, Shrestha S, Schumacher J, Kempf MC. A qualitative study on factors impacting HIV care adherence among postpartum HIV-infected women in the rural southeastern USA. AIDS Care. 2014; 26:574-581.